Page 148 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer
P. 148
20. Merrill RM, Brawley OW. Prostate cancer 31. Clegg LX, Li FP, Hankey BF, Chu K,
incidence and mortality rates among white Edwards BK. Cancer survival among US
and black men. Epidemiology 1997;8:126- whites and minorities: a SEER
131. (Surveillance, Epidemiology, and End
Results) Program population-based study.
21. Farkas A, Schneider D, Perrotti M, et al.
National trends in the epidemiology of Arch Intern Med. 2002;162:1985-1993.
prostate cancer, 1973 to 1994: evidence for 32. Merrill RM, Morris MK. Prevalence-
the effectiveness of prostate-specific antigen corrected prostate cancer incidence rates and
screening. Urology 1998;52:444-448. trends. Am J Epidemiol 2002;155:148-152.
22. Perrotti M, Rabbani F, Farkas A, et al. 33. Collin SM, Martin RM, Metcalfe C, et al.
Trends in poorly differentiated prostate Prostate-cancer mortality in the USA and
cancer 1973 to 1994: observations from the UK in 1975-2004: an ecological study.
Surveillance, Epidemiology and End Results Lancet Oncol 2008;9:445-452.
database. J Urol 1998;160:811-815.
34. Sarma AV, Schottenfeld D. Prostate cancer
23. Dennis LK, Resnick MI. Analysis of recent incidence, mortality, and survival trends in
trends in prostate cancer incidence and the United States: 1981-2001. Semin Urol
mortality. Prostate 2000;42:247-252. Oncol 2002;20:3-9.
24. Merrill RM, Lyon JL. Explaining the 35. Lu-Yao GL, Greenberg ER. Changes in
difference in prostate cancer mortality rates prostate cancer incidence and treatment in
between white and black men in the United USA. Lancet 1994;343:251-254.
States. Urology 2000;55:730-735.
36. Harlan L, Brawley O, Pommerenke F, et al.
25. Clegg LX, Feuer EJ, Midthune DN, et al. Geographic, age, and racial variation in the
Impact of reporting delay and reporting error treatment of local/regional carcinoma of the
on cancer incidence rates and trends. J Natl prostate. J Clin Oncol 1995;13:93-100.
Cancer Inst 2002;94:1537-1545.
37. Jani AB, Master VA, Rossi PJ, et al. Grade
26. Stephenson RA. Prostate cancer trends in migration in prostate cancer: an analysis
the era of prostate-specific antigen. An using the Surveillance, Epidemiology, and
update of incidence, mortality, and clinical End Results registry. Prostate Cancer
factors from the SEER database. Urol Clin Prostatic Dis 2007;10:347-351.
North Am 2002;29:173-181.
38. Welch HG, Albertsen PC. Prostate cancer
27. Escobedo LG, Rivas SD, Holmes MD. diagnosis and treatment after the
Prostate cancer mortality in Connecticut, introduction of prostate-specific antigen
Iowa and New Mexico African American screening: 1986-2005. J Natl Cancer Inst
men. Cancer Detect Prev 2004;28:375-380. 2009;101:1325-1329.
28. McDavid K, Lee J, Fulton JP, et al. Prostate 39. Devesa SS, Blot WJ, Stone BJ, et al. A,
cancer incidence and mortality rates and Tarone RE, Fraumeni JF, Jr. Recent cancer
trends in the United States and Canada. trends in the United States. J Natl Cancer
Public Health Rep 2004;119:174-186. Inst. 1995;87:175-182.
29. Hayat MJ, Howlader N, Reichman ME, et 40. Merrill RM, Stephenson RA. Trends in
al. Cancer statistics, trends, and multiple mortality rates in patients with prostate
primary cancer analyses from the cancer during the era of prostate specific
Surveillance, Epidemiology, and End antigen screening. J Urol. 2000;163:503-
Results (SEER) Program. Oncologist 510.
2007;12:20-37.
41. Miller DC, Gruber SB, Hollenbeck BK, et
30. Jani AB, Johnstone PA, Liauw SL, et al. al. Incidence of initial local therapy among
Age and grade trends in prostate cancer men with lower-risk prostate cancer in the
(1974-2003): a Surveillance, Epidemiology, United States. J Natl Cancer Inst
and End Results Registry analysis. Am J 2006;98:1134-1141.
Clin Oncol 2008;31:375-378.
94
